The ACTolog<sup>®</sup> trial (IMA101-101) is a clinical pilot trial to demonstrate tolerability and feasibility of a multi-target ACT approach. The ACTolog<sup>®</sup> concept is based on selecting and expanding a patient’s own autologous T cells dependent on the detection of ACTolog<sup>®</sup> targets in the patient’s tumor tissue. The ACTolog<sup>®</sup> approach was designed as the first known multi-target precision immunotherapy delivering a proof-of-principle for a next-generation multi-TCR-T approach using highly potent TCRs as in <a href="https://www.globenewswire.com/… target="_blank" rel="nofollow noopener noreferrer">Immatics’ lead product class ACTengine<sup>®</sup> (TCR-T)</a>.</p> <p align="justify">More information on the clinical trials can be found at the following links: <a href="https://www.globenewswire.com/… target="_blank" rel="nofollow noopener noreferrer">www.immatics.com/…> and <a href="https://www.globenewswire.com/… target="_blank" rel="nofollow noopener noreferrer">www.clinicaltrials.gov</…> <p align="justify"><strong>Forward-Looking Statements:</strong></p> <p align="justify">Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics’ future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics’ focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including general economic conditions and other risks, uncertainties and factors set forth in filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.</p>
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
For regular updates about Immatics, visit www.immatics.com. You can also follow us on Twitter and LinkedIn.
immatics biotechnologies GmbH
Telefon: +49 (7071) 5397-0
Telefax: +49 (7071) 5397-900
Telefon: +49 (89) 540415-606
Telefon: +1 (346) 204-5409